Clinical Trials Browser

Phase 2 × Hypereosinophilic Syndrome × Other hematologic neoplasm × Clear all

Leukemia, Mastocytosis, Myelodysplastic Syndromes, Polycythemia Vera, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Primary Myelofibrosis

NCT00171912 2017-02-23

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

Phase 2 Completed

38 enrolled

MyeloidOther hematologic neoplasmSarcomaThoracic

Lung Neoplasms, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Dermatofibrosarcoma, Mastocytosis, Systemic, Leukemia, Myelomonocytic, Juvenile

NCT00154388 2016-11-18

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Phase 2 Completed

185 enrolled

BreastDermatologicGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Malignant mesenchymal tumor, Adenocarcinoma, Brenner Tumor, Carcinoma, Renal Cell, Chondrosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Hemangiopericytoma, Hemangiosarcoma, Leiomyosarcoma, Leukemia, Mast-Cell, Liposarcoma, Mastocytosis, Melanoma, Mesothelioma, Multiple Myeloma, Pleural Neoplasms, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Thymoma, Hypereosinophilic Syndrome, Sarcoma, Endometrial Stromal, Dermatofibrosarcoma, Rhabdomyosarcoma, Embryonal, Seminoma, Carcinoma, Ductal, Breast, Neurofibrosarcoma, Primary Myelofibrosis, Small Cell Lung Carcinoma

NCT00483067 2012-08-02

2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)

Phase 2 Completed

13 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Hypereosinophilic Syndrome

Clinical Trials

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)